Food and Drug Law Journal 2024 Symposium
From Past to Progress: Envisioning the Future of FDA Law and Regulation
November 13, 2024 | In-Person & Virtual Event
Overview
The Food and Drug Law Institute (FDLI) is pleased to host the Food and Drug Law Journal 2024 Symposium, “From Past to Progress: Envisioning the Future of FDA Law and Regulation.” The Symposium will celebrate FDLI’s 75th Anniversary and its enduring contributions to the field of food and drug law by exploring the future of FDA regulation while reflecting on its historical foundations.
FDA is responsible for protecting the public health by regulating food, drugs, biologics, medical devices, tobacco, cosmetics, and more. As we look ahead to the next era of food and drug law, it is crucial to consider how FDA laws and regulations will adapt to emerging technologies, evolving public health challenges, and shifting societal expectations.
FDLI and the Symposium Planning Committee thanks those who participated in the Call for Abstracts. Accepted authors must submit a draft for discussion by October 21, for discussion at the program taking place in Washington, DC on November 13, 2024. Finalized papers will be considered for publication in a future issue of the Food and Drug Law Journal.
The Food and Drug Law Journal (FDLJ) is the publication sponsor for this Symposium and reserves a right of first refusal to publish accepted papers, subject to the editorial review process. All final papers should be under 25,000 words in length, double-spaced, and in Times New Roman font. FDLJ requires footnotes that conform with the 21st edition of The Bluebook: A Uniform System of Citation. Additional author guidelines are available here. Questions regarding submission requirements may be directed to [email protected].
Planning Committee
Brigid Bondoc, Morrison & Foerster LLP.
Michelle Divelbiss, Covington & Burling LLP
Bridget C.E. Dooling, The Ohio State University Moritz College of Law
William M. Janssen, Charleston School of Law
John F. Johnson III, Shook, Hardy & Bacon LLP
Markham C. Luke, FDA – CDER
Cynthia L. Meyer, Kleinfeld, Kaplan & Becker, LLP
Adam Muchmore, Penn State Law
Daniel Orr, Wilson Sonsini Goodrich & Rosati
Shy Shorer, NIH, NCI, CCR
Eric Solowey, Parexel International Corporation
Andrew Wasson, Haug Partners LLP
